NK-Cell Biofactory as an Off-the-Shelf Cell-based Vector for Targeted In Situ Synthesis of Engineered Proteins.

The NK-92MI, a fast-growing cytolytic cell line with a track record of exerting clinical efficacy, is transformed into a vector for synthesizing calibrated amounts of desired engineered proteins at our disease site, that is, NK-cell Biofactory. This provides an allogeneic option to the previously published T-cell-based living vector that is limited by high manufacturing cost and product variability. The modularity of this pathway, which combines a "target" receptor with an "effector" function, enables reprogramming of the NK-cell Biofactory to target diseases with specific molecular biomarkers, such as cancer, viral infections, or auto-immune disorders, and overcome barriers that may affect the advancement of NK-cell therapies.

[1]  Krishanu Saha,et al.  Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies , 2020, Stem Cell Research & Therapy.

[2]  H. Javitz,et al.  Lentivirus Manufacturing Process for Primary T‐Cell Biofactory Production , 2020, Advanced biosystems.

[3]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[4]  H. Javitz,et al.  Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function , 2020, Advanced biosystems.

[5]  R. Rockne,et al.  Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data , 2020, Journal of the Royal Society Interface.

[6]  J. Boudreau,et al.  Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer , 2019, Front. Immunol..

[7]  M. Caligiuri,et al.  Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion , 2019, Nature.

[8]  J. Chavez,et al.  CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products , 2019, Therapeutic advances in hematology.

[9]  C. Rooney,et al.  NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors , 2019, Cancer Immunology Research.

[10]  H. Javitz,et al.  Modular Antigen‐Specific T‐cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins , 2018, Advanced biosystems.

[11]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[12]  B. Rini,et al.  Individualized dosing with axitinib: rationale and practical guidance. , 2018, Future oncology.

[13]  T. D. de Gruijl,et al.  The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments , 2017, Front. Immunol..

[14]  W. Wels,et al.  Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity , 2017, Front. Immunol..

[15]  B. Rini,et al.  Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology? , 2016, Clinical Cancer Research.

[16]  Kristina M. Ilieva,et al.  Targeting folate receptor alpha for cancer treatment , 2016, Oncotarget.

[17]  W. Wels,et al.  NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[18]  H. Klingemann,et al.  Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells , 2016, Front. Immunol..

[19]  C. Kalberer,et al.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control , 2015, Oncoimmunology.

[20]  D. Kaufman,et al.  Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity , 2015, Front. Immunol..

[21]  M. Cheng,et al.  NK cell-based immunotherapy for malignant diseases , 2013, Cellular and Molecular Immunology.

[22]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[23]  I. Pastan,et al.  Recognition of Mesothelin by the Therapeutic Antibody MORAb-009 , 2012, The Journal of Biological Chemistry.

[24]  J. Verweij,et al.  Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? , 2007, The oncologist.

[25]  S. Bates,et al.  Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics , 2007, Anti-cancer drugs.

[26]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[27]  L. Grochow,et al.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. , 2002, Journal of the National Cancer Institute.

[28]  Mitchell Ho,et al.  Mesothelin targeted cancer immunotherapy. , 2008, European journal of cancer.

[29]  H. Klingemann,et al.  Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. , 2003, Cytotherapy.